Fairmount Healthcare Co-Invest II L.P.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$15M
Investors
14
Min Invest
$1
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Fairmount Healthcare Co-Invest II L.P. is a Delaware limited partnership that filed a Form D with the SEC on August 21, 2023, describing itself as a hedge fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(7) and covers equity and pooled investment fund interests. Fairmount Healthcare Co-Invest II L.P. reported $15,173,000 sold from 14 investors of a $15,173,000 total offering as of the Form D filed August 21, 2023. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
closed
Fund family Part of the Fairmount Healthcare Co Invest family: 7 vehicles across 6 generations · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Fairmount Healthcare Co-Invest II GP LLC
Executive Officer, Promoter · West Conshohocken, PA
General Partner of the Issuer
Peter Harwin
Executive Officer, Promoter · West Conshohocken, PA
Managing Member of the General Partner and Investment Manager of the Issuer
Tomas Kiselak
Executive Officer, Promoter · West Conshohocken, PA
Managing Member of the General Partner and Investment Manager of the Issuer
Fairmount Funds Management LLC
Executive Officer · West Conshohocken, PA
Investment Manager of the Issuer
Questions About Fairmount Healthcare Co-Invest II L.P.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Fairmount Healthcare Co-Invest II L.P.?
Fairmount Healthcare Co-Invest II L.P. is a Delaware limited partnership that filed a Form D with the SEC on August 21, 2023 as a hedge fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of equity and pooled investment fund interests.
Is Fairmount Healthcare Co-Invest II L.P. legit?
AltStreet does not rate legitimacy; it reports the public record. Fairmount Healthcare Co-Invest II L.P. filed a Form D with the SEC on August 21, 2023 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $15,173,000 sold to 14 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Fairmount Healthcare Co-Invest II L.P. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Fairmount Healthcare Co-Invest II L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Fairmount Healthcare Co-Invest II L.P. raised?
Fairmount Healthcare Co-Invest II L.P. reported $15,173,000 sold from 14 investors of a $15,173,000 total offering as of the Form D filed August 21, 2023.
Who can invest in Fairmount Healthcare Co-Invest II L.P.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1.
What is the minimum investment in Fairmount Healthcare Co-Invest II L.P.?
The Form D lists $1 as the minimum investment accepted from any outside investor as of August 21, 2023. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Fairmount Healthcare Co-Invest II L.P. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Who is behind Fairmount Healthcare Co-Invest II L.P.?
The Form D lists 4 related persons: Fairmount Healthcare Co-Invest II GP LLC, executive officer, promoter (General Partner of the Issuer); Peter Harwin, executive officer, promoter (Managing Member of the General Partner and Investment Manager of the Issuer); Tomas Kiselak, executive officer, promoter (Managing Member of the General Partner and Investment Manager of the Issuer); Fairmount Funds Management LLC, executive officer (Investment Manager of the Issuer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Fairmount Healthcare Co-Invest II L.P. located?
The issuer's address on its SEC filings is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428. Its phone number of record is 267-262-5300. It is organized under the laws of Delaware.
How long is the Fairmount Healthcare Co-Invest II L.P. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
How large is Fairmount Healthcare Co-Invest II L.P.?
The issuer declined to disclose its net asset value range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.